Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €50.32 EUR
Change Today +0.402 / 0.81%
Volume 0.0
EC8 On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 2:20 AM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

conmed corp (EC8) Snapshot

Open
€50.44
Previous Close
€49.92
Day High
€50.44
Day Low
€50.32
52 Week High
05/28/15 - €50.44
52 Week Low
08/13/14 - €27.12
Market Cap
1.4B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
27.6M
EX-Date
03/12/15
P/E TM
--
Dividend
€0.82
Dividend Yield
1.29%
Current Stock Chart for CONMED CORP (EC8)

conmed corp (EC8) Related Bloomberg News

View More Bloomberg News

conmed corp (EC8) Related Businessweek News

No Related Businessweek News Found

conmed corp (EC8) Details

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures and monitoring in the United States, Canada, the United Kingdom, Japan, Australia, and internationally. The company offers sports medicine products, such as powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, metal and bio absorbable implants, and related disposable products and fluid management systems; powered surgical instruments for use in large and small bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; and sports biologics and tissues. It also provides electrosurgical generators, hand pieces, smoke management systems, and accessories for surgical needs; and endomechanical instrumentation products that offer various instruments comprising trocars, clip appliers, scissors, and surgical staplers used in the minimally invasive laparoscopic and gynecological surgery, as well as an uterine manipulator for use in the laparoscopic hysterectomies and other gynecologic laparoscopic procedures. In addition, the company provides mucosal management devices, forceps, scope management accessories, bronchoscopy devices, dilatation, stricture management devices, hemostasis, biliary devices, and polypectomy; pulse oximetry equipment and sensors, ECG electrodes and cables, cardiac defibrillation and pacing pads, and blood pressure cuffs; suction instruments and tubing for use in the operating room; IV products for use in the critical care areas of the hospital; pulmonary monitoring products; and imaging systems for use in the minimally invasive orthopedic and general surgery procedures. The company’s products are used by surgeons and physicians in orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. CONMED Corporation was founded in 1970 and is headquartered in Utica, New York.

3,500 Employees
Last Reported Date: 02/23/15
Founded in 1970

conmed corp (EC8) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $262.4K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $328.7K
Executive Vice President of Legal Affairs and...
Total Annual Compensation: $299.0K
Compensation as of Fiscal Year 2014.

conmed corp (EC8) Key Developments

CONMED Corporation Appoints Peter Shagory as Executive Vice President, Strategy and Corporate Development

CONMED Corporation announced that it has appointed Peter Shagory as the company’s Executive Vice President, Strategy and Corporate Development. Mr. Shagory will be responsible for managing CONMED’s global business development and strategic business opportunities. Mr. Shagory brings to CONMED more than 20 years of experience in healthcare venture investing and mergers and acquisitions through his previous venture capital, investment banking and corporate roles. Most recently, Mr. Shagory led the strategy and business development efforts for Cardinal Health’s Medical Products Group within the Medical Segment, where he played a key role in Cardinal Health’s entry into the interventional cardiovascular and the advanced wound care categories. Prior to that, Mr. Shagory led the healthcare and life sciences investment effort at Baird Venture Partners, focusing on medical technology and research tools and diagnostics.

CONMED Corporation Seeks Acquisitions

CONMED Corporation (NasdaqGS:CNMD) is looking for acquisition. Curt Hartman, President and Chief Executive Officer of CONMED Corporation states, "We also announced that we would be acquisitive. We have cash generation. We think we can do small tuck-in acquisitions to each of our core businesses. Luke has been serving a dual purpose as CFO as well as my head of BD and working with the business leaders, facilitating that process."

CONMED Corporation Enters into Fourth Amended and Restated Credit Agreement Providing for $450.0 Million Secured Revolving Credit Facility

On April 28, 2015, CONMED Corporation (the Company), as a borrower, entered into a fourth amended and restated credit agreement providing for a $450.0 million secured revolving credit facility (the Credit Agreement), among the Company, the foreign subsidiary borrowers from time to time parties thereto, the several lenders from time to time parties thereto and JPMorgan Chase Bank, N.A., as administrative agent (the Administrative Agent). The Credit Agreement comprises commitments from eight financial institutions. The Credit Agreement permits the Company to designate foreign subsidiaries as additional borrowers. The Credit Agreement expires on April 28, 2020, at which time all outstanding amounts will be due and payable. There is $270 million outstanding under the Credit Agreement. The Credit Agreement amends and restates a credit agreement dated January 17, 2013 that was due to expire on January 17, 2018. The Company's borrowings under the Credit Agreement can be used for all general corporate purposes and will bear interest at variable rates dependent on the Company's consolidated senior leverage ratio, calculated according to a base rate or a Eurocurrency rate plus an applicable margin, as the case may be. The Company must pay facility commitment fees quarterly in arrears at rates dependent on the Company's consolidated senior leverage ratio. The applicable margin and rate for the facility commitment are set at agreed pricing levels until February 2016 and will thereafter fluctuate dependent on the Company's consolidated senior leverage ratio. Borrowings under the Credit Agreement are secured by assets and rights of the Company and certain of its subsidiaries. The Credit Agreement contains customary covenants for transactions of this type, including three financial covenants: (i) a consolidated senior leverage ratio, as defined in the Credit Agreement, that must be maintained at a level of not greater than 3.5 to 1; (ii) a consolidated total leverage ratio, as defined in the Credit Agreement, that must be maintained at a level of not greater than 4 to 1; and (iii) a consolidated fixed charge coverage ratio, as defined in the Credit Agreement, that must be maintained at a level of not less than 2.5 to 1. In addition, as a condition precedent to each borrowing made under the Credit Agreement, as of the date of such borrowing, (i) no default or event of default shall have occurred and be continuing on such date or after giving effect to the extensions of credit requested to be made on such date and (ii) the Company is to reaffirm that the representations and warranties made in the Credit Agreement are true and correct in all material respects. The Credit Agreement provides for customary events of default, including failure to pay any principal or interest when due, failure to comply with covenants, any representation made by the Company proving to be incorrect, defaults relating to other indebtedness of at least $25,000,000 in the aggregate, certain insolvency and receivership events affecting the Company or its subsidiaries, judgments not covered by insurance in excess of $25,000,000 in the aggregate being rendered against the Company or its subsidiaries, the acquisition by any person of more than 35% of the outstanding common stock of the Company, and the incurrence of certain ERISA liabilities that would reasonably be expected to have a material adverse effect.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EC8:GR €50.32 EUR +0.402

EC8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ascom Holding AG SFr.16.65 CHF 0.00
Integra LifeSciences Holdings Corp $67.68 USD +0.93
Masimo Corp $35.86 USD +0.41
NuVasive Inc $48.78 USD +0.30
Wright Medical Group Inc $27.22 USD +0.31
View Industry Companies
 

Industry Analysis

EC8

Industry Average

Valuation EC8 Industry Range
Price/Earnings 51.0x
Price/Sales 2.1x
Price/Book 2.6x
Price/Cash Flow 50.7x
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CONMED CORP, please visit www.conmed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.